For citations:
Samoylenko I.V., Pokataev I.А., Zhukova L.G., Stroyakovsky D.L., Orlova R.V., Mudunov А.М., Pak М.В., Zernova Е.V., Sobolev А.V., Mochalova А.S., Alekseev B.Ya., Sekacheva М.I., Ledin Е.V., Petkova А.V., Khanonina Е.К., Podolyakina А.I., Razzhivina V.А. Study of the pharmacokinetics, pharmacodynamics, and safety of the biosimilar pembrolizumab RPH-075 compared to Keytruda® in patients with malignant neoplasms. Malignant tumours. 2024;14(1):56-66. (In Russ.) https://doi.org/10.18027/2224-5057-2024-14-1-56-66
Email this article 